Bruker Corporation Aktie News

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced new orders for advanced Nuclear Magnetic Resonance (NMR) instrumentation from the New York Structural Biology Center (NYSBC), the University of Delaware and Northwestern University. Supported by the National Institutes of Health (NIH) and the National Science Foundation (NSF), these high-perform...

Six new preferred stock and baby bond offerings were tracked, with yields ranging from 6.375% to 8.875%. Top-quality preferreds (Compliance Score 10) are trading at a 2.8% discount to par, offering a current yield of 6.7%. Investors can often buy new preferred IPOs at wholesale prices on the OTC, minimizing capital loss risk if prices drop.

Bruker Corporation 6.375 PREF SER A is a new 6.375% mandatory convertible preferred stock from Bruker, offering fixed income but closely tied to BRKR's common stock performance. Bruker's fundamentals have weakened, with declining performance and a dividend cushion that's thinner than ideal for preferred holders. Option-adjusted yield to maturity is unappealing versus peer term preferreds of com...

Medical device and diagnostics company Bruker (BRKR -11.68%) wasn't looking like the cure for any investor's ailments on Wednesday. The stock was hit with an assertive sell-off from the market, leaving it with a nearly 12% price decline on the session.

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (“Bruker”) (Nasdaq: BRKR) today announced the pricing of its previously announced public offering of $600.0 million of 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock”). Bruker has granted the underwriters a 30-day option to purchase up to an additi...

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (“Bruker”) (Nasdaq: BRKR) today announced it has commenced a public offering, subject to market and other conditions, of $600.0 million of Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the “Mandatory Convertible Preferred Stock”). Bruker expects to grant the underwriters a 30-day option to purcha...

Michael Burry, the legendary “Big Short” investor and founder of Scion Asset Management has revealed a substantial reshuffle in his Q2 2025 holdings, adding heavyweight names across healthcare, retail, biotech, and e-commerce while trimming his largest position.

Bruker faces significant headwinds due to NIH funding cuts, heavy reliance on academia, and declining financial performance versus peers. Despite operational challenges and a sharp drop in valuation, Bruker's NMR technology moat and long-term potential remain intact. I'm accumulating shares gradually at these low valuations, confident in mean reversion and management's ability to consolidate ac...